Work

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC

Year: 2018

Type: article

Study design: Observational Study

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.06.005

Authors: Jessica J. Lin, Viola W. Zhu, Adam J. Schoenfeld, Beow Y. Yeap, Ashish Saxena, Lorin A. Ferris, Ibiayi Dagogo-Jack, Anna F. Farago, Angela Taber, Anne Traynor, Smitha Menon, Justin F. Gainor, Jochen K. Lennerz, Andrew J. Plodkowski, Subba R. Digumarthy, Sai-Hong Ignatius Ou, Alice T. Shaw, Gregory J. Riely

Institutions: Massachusetts General Hospital, University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Chao Family Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Lifespan, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Medical College of Wisconsin

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, University of California, Irvine, National Cancer Institute

Awards: G417794582, Cancer Center Support Grant, Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

OpenAlex ID: W2809495979

FWCI: 7.27

Cites: 24

Cited by: 82

Related to: 10